US-based Thermo Fisher Scientific has announced the launch of an automated, next-generation sequencing (NGS) platform, CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer.
The system, designed for use in clinical laboratories, is capable of delivering results in less than a single day.
The sequencer is designed for use in both diagnostic testing and clinical research.
Thermo Fisher Scientific clinical next-generation sequencing and oncology president Garret Hampton said: “Next-generation sequencing has become an essential tool to bring the promise of precision medicine therapies to patients.
“With the automated, easy-to-use Genexus Dx Integrated Sequencer, any hospital – including regional and community hospitals – can bring NGS in-house, giving clinicians access to timely, comprehensive genomic profiling results.
“With faster answers, the results can aid clinicians in their patient management decision making which may include therapeutic options.”
Thermo Fisher is also working on an overall sample-to-report diagnostic workflow and a portfolio of clinically validated assays to enhance physicians’ access to rapid NGS data.
The assays, which will also be developed for comprehensive genomic profiling and hemato-oncology, will be based on the Genexus System.
The firm initially introduced the system for research purposes in 2019 as the first fully integrated NGS platform capable of delivering results in as little as 24 hours.
With its automated workflow, the platform has the ability to minimise user intervention and the potential for human error.
Recently, Thermo Fisher Scientific introduced a new large-volume electroporation system called Gibco CTS Xenon Electroporation System for cell therapy developers to move from clinical development to commercial manufacturing with ease.
